AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7807244 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific intervention details provided)
Number of subjects: 102
Study 2642658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 30
Study 2642658 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 30
Study 1251322 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagotomy and drainage
Number of subjects: 157
Study 1251322 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagotomy and hemigastrectomy
Number of subjects: 157
Study 1251322 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy without drainage
Number of subjects: 157
Study 1251322 — intervention group
Group type: COMPARATOR
Intervention: Simple closure
Number of subjects: 157
Study 11229669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 9014
Study 11229669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 30832665 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance card
Number of subjects: 1919
Study 30832665 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment voucher
Number of subjects: 1919
Study 30832665 — intervention group
Group type: COMPARATOR
Intervention: No health insurance
Number of subjects: 1919
Study 30422784 — intervention group
Group type: EXPERIMENTAL
Intervention: DAD mobile BAI that included personalized feedback and interactive text messaging
Number of subjects: 84
Study 30422784 — intervention group
Group type: COMPARATOR
Intervention: DAD information
Number of subjects: 84
Study 27159290 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (20 mL Exparel + 20 mL 0.9% saline)
Number of subjects: 32
Study 27159290 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine hydrochloride (20 mL 0.5% bupivacaine HCl + 20 mL 0.9% saline)
Number of subjects: 32
Study 24604894 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation environment (MSSE) group
Number of subjects: 30
Study 24604894 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized activities (activity) group
Number of subjects: 30
Study 24604894 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 22850352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol extended release (ER)
Number of subjects: 0
Study 22850352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22850352 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone controlled release (CR)
Number of subjects: 0
Study 19432875 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP-lowering intervention
Number of subjects: 10
Study 16814935 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use during tobacco cessation treatment
Number of subjects: 101
Study 16814935 — intervention group
Group type: COMPARATOR
Intervention: Pre-enrollment alcohol use
Number of subjects: 101
Study 15701778 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex-dose group (topiramate with adjustable AED cotherapy)
Number of subjects: 599
Study 15701778 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose group (topiramate with fixed AED cotherapy)
Number of subjects: 599
Study 12213686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate depression
Number of subjects: 2558
Study 12213686 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depressive syndromes
Number of subjects: 2558
Study 9456212 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration search procedure
Number of subjects: 0
Study 9456212 — intervention group
Group type: COMPARATOR
Intervention: Ping-pong search procedure
Number of subjects: 0
Study 8747898 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (4.6%) + Plasmalyte (Group A, n = 32)
Number of subjects: 93
Study 8747898 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygeline (Hemaccel) + Plasmalyte (Group P, n = 29)
Number of subjects: 93
Study 8747898 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid (Plasmalyte) alone (Group C, n = 32)
Number of subjects: 93
Study 2709981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting belt
Number of subjects: 9
Study 2709981 — intervention group
Group type: COMPARATOR
Intervention: No lifting belt
Number of subjects: 9
Study 938161 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 treatment
Number of subjects: 213
Study 938161 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 213
Study 31912752 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation programme (3 weeks inpatient stay + 12 weeks home-based activities)
Number of subjects: 165
Study 31912752 — intervention group
Group type: COMPARATOR
Intervention: Existing rehabilitation programme (4 weeks inpatient stay)
Number of subjects: 165
Study 31912752 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation programme
Number of subjects: 165
Study 31912752 — intervention group
Group type: COMPARATOR
Intervention: Existing rehabilitation programme
Number of subjects: 165
Study 30763457 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Grain (WG) diet
Number of subjects: 13
Study 30763457 — intervention group
Group type: COMPARATOR
Intervention: Refined-Grain (RG) diet
Number of subjects: 13
Study 29351103 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28929695 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragali Radix group 1 (10 g•d⁻¹)
Number of subjects: 226
Study 28929695 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragali Radix group 2 (5 g•d⁻¹)
Number of subjects: 226
Study 28929695 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional medical treatment)
Number of subjects: 226
Study 25126034 — intervention group
Group type: EXPERIMENTAL
Intervention: Home portable monitoring (WatchPAT200)
Number of subjects: 75
Study 25126034 — intervention group
Group type: COMPARATOR
Intervention: In-laboratory polysomnography (PSG)
Number of subjects: 75
Study 22171802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice containing 90 mmol Na (B)
Number of subjects: 23
Study 22171802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice containing 140 mmol Na (C)
Number of subjects: 23
Study 22171802 — intervention group
Group type: COMPARATOR
Intervention: Sodium-free tomato juice (A)
Number of subjects: 23
Study 19294951 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep (10 h time in bed)
Number of subjects: 24
Study 19294951 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (mean 7.09 h time in bed)
Number of subjects: 24
Study 17213242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adelaide Driving Self-Efficacy Scale (ADSES)
Number of subjects: 81
Study 17213242 — intervention group
Group type: COMPARATOR
Intervention: ADSES scores for stroke patients
Number of subjects: 81
Study 17213242 — intervention group
Group type: COMPARATOR
Intervention: ADSES scores for participants who passed or failed the on-road assessment
Number of subjects: 81
Study 15666257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylator EM-100 (manual mode)
Number of subjects: 40
Study 15666257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylator EM-100 (automatic mode)
Number of subjects: 40
Study 15666257 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve device
Number of subjects: 40
Study 11300580 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrity-repair exercise after the threat
Number of subjects: 0
Study 11300580 — intervention group
Group type: COMPARATOR
Intervention: Threat of deliberative mind-set induced uncertainty
Number of subjects: 0
Study 11300580 — intervention group
Group type: COMPARATOR
Intervention: Mortality salience and temporal discontinuity threats
Number of subjects: 0
Study 11300580 — intervention group
Group type: COMPARATOR
Intervention: Uncertainty-related threats
Number of subjects: 0
Study 9399755 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.i.d., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d. (RAC)
Number of subjects: 100
Study 9399755 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.i.d., metronidazole 250 mg t.i.d., and tetracycline 500 mg t.i.d. (RMT)
Number of subjects: 100
Study 8198928 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 9
Study 8198928 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg)
Number of subjects: 9
Study 8198928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2907080 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PROP) 80 mg b.i.d.
Number of subjects: 28
Study 2907080 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (ATEN) 100 mg o.d.
Number of subjects: 28
Study 2907080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 28
Study 29276031 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training with a manikin in a hospital bed
Number of subjects: 108
Study 29276031 — intervention group
Group type: COMPARATOR
Intervention: CPR training with a manikin on the floor
Number of subjects: 108
Study 29276031 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised working position (regardless of training method)
Number of subjects: 108
Study 29276031 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-optimised working position (regardless of training method)
Number of subjects: 108
Study 28185775 — intervention group
Group type: COMPARATOR
Intervention: Gravity group (n=50)
Number of subjects: 150
Study 28185775 — intervention group
Group type: COMPARATOR
Intervention: 20-lbf group (n=50)
Number of subjects: 150
Study 28185775 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-lbf group (n=50)
Number of subjects: 150
Study 26691535 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT + TAU
Number of subjects: 152
Study 26691535 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 152
Study 23239126 — intervention group
Group type: EXPERIMENTAL
Intervention: Group culture of good and poor quality embryos separately (Method B)
Number of subjects: 874
Study 23239126 — intervention group
Group type: COMPARATOR
Intervention: Group culture of embryos randomly regardless of quality (Method A)
Number of subjects: 874
Study 23239126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 874
Study 21608219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo Capsule (TXL)
Number of subjects: 160
Study 21608219 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 160
Study 18424988 — intervention group
Group type: COMPARATOR
Intervention: Rigid registration without correction of geometric distortion
Number of subjects: 11
Study 18424988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid registration with compensation for geometric distortion
Number of subjects: 11
Study 18424988 — intervention group
Group type: COMPARATOR
Intervention: Comparison of alignment accuracy
Number of subjects: 11
Study 17238499 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminders
Number of subjects: 0
Study 17238499 — intervention group
Group type: COMPARATOR
Intervention: Postal reminders
Number of subjects: 0
Study 12960927 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded reoxygenation (paO2: 50‐70 mmHg, n=10)
Number of subjects: 19
Study 12960927 — intervention group
Group type: COMPARATOR
Intervention: Conventional hyperoxic reoxygenation (paO2: >250 mmHg, n=9)
Number of subjects: 19
Study 10653873 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of adjuvant chemotherapy within 20 days after surgery (599 patients, 84 with ER-absent tumors)
Number of subjects: 1788
Study 10653873 — intervention group
Group type: COMPARATOR
Intervention: Conventional initiation of adjuvant chemotherapy 21 to 86 days after surgery (1,189 patients, 142 with ER-absent tumors)
Number of subjects: 1788
Study 10653873 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of chemotherapy for ER-expressing tumors (1,562 patients)
Number of subjects: 1788
Study 9209181 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25-MJ liquid meal
Number of subjects: 11
Study 9209181 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.92-MJ liquid meal
Number of subjects: 11
Study 9209181 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding (general)
Number of subjects: 11
Study 8218004 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms desogestrel and 20 micrograms ethinyl oestradiol (Mercilon)
Number of subjects: 1000
Study 8218004 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms desogestrel and 30 micrograms ethinyl oestradiol (Marvelon/Desolett)
Number of subjects: 1000
Study 3302842 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (6 weekly sessions of 75 min duration in progressive relaxation)
Number of subjects: 40
Study 3302842 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 40
Study 31609666 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS
Number of subjects: 59
Study 31609666 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 59
Study 30646281 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized program for identification, assessment, and treatment of osteoporosis led by a trained coordinating nurse.
Number of subjects: 82578
Study 30646281 — intervention group
Group type: COMPARATOR
Intervention: Control period (2008-2015) without the intervention.
Number of subjects: 82578
Study 26945918 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver outcome score predicting 5-year liver-related death
Number of subjects: 617
Study 26945918 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver outcome score predicting 5-year liver decompensation
Number of subjects: 617
Study 26945918 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver outcome score predicting 5-year hepatocellular carcinoma (HCC) occurrence
Number of subjects: 617
Study 23990572 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (600 mg/d) plus standard antituberculosis treatment (rifampicin and isoniazid)
Number of subjects: 307
Study 23990572 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (600 mg/d) alone
Number of subjects: 307
Study 23990572 — intervention group
Group type: COMPARATOR
Intervention: Standard antituberculosis treatment (rifampicin and isoniazid)
Number of subjects: 307
Study 21986244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored brief tobacco cessation interventions by lay health influencers
Number of subjects: 80
Study 21986244 — intervention group
Group type: EXPERIMENTAL
Intervention: Training curriculum for lay health influencers
Number of subjects: 80
Study 19783599 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) for 1 year post-transplant
Number of subjects: 388
Study 19783599 — intervention group
Group type: COMPARATOR
Intervention: No Isoniazid (Control group)
Number of subjects: 388
Study 19166443 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT 2 g
Number of subjects: 1611
Study 19166443 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN 1 g
Number of subjects: 1611
Study 19166443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1611
Study 16174011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt Table Test (TTT) positive
Number of subjects: 81
Study 16174011 — intervention group
Group type: COMPARATOR
Intervention: Tilt Table Test (TTT) negative
Number of subjects: 81
Study 16174011 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR activation
Number of subjects: 81
Study 12373599 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit statement mentioning 'a computer', 'chance', and 'not the doctor's or patient's decision'
Number of subjects: 741
Study 12373599 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinct statement that played down the role of 'chance'
Number of subjects: 741
Study 12373599 — intervention group
Group type: COMPARATOR
Intervention: Analogy of 'a computer will perform the equivalent of tossing a coin to allocate you to one of two methods of treatment'
Number of subjects: 741
Study 9697553 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led health education course
Number of subjects: 0
Study 9697553 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 0
Study 7510728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentastarch
Number of subjects: 29
Study 7510728 — intervention group
Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 29
Study 2675752 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 200 mg orally daily at bedtime
Number of subjects: 30
Study 2675752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2675752 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 30
Study 174244 — intervention group
Group type: EXPERIMENTAL
Intervention: DBcAMP administered intravenously at 10 mg/min for 20 min
Number of subjects: 10
Study 174244 — intervention group
Group type: EXPERIMENTAL
Intervention: DBcAMP administered intravenously at 20 mg/min for 20 min
Number of subjects: 10
Study 7362696 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (2 g/day)
Number of subjects: 14
Study 7362696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (7.5 mg/day)
Number of subjects: 14
Study 7362696 — intervention group
Group type: COMPARATOR
Intervention: PAS-C (6-8 g/day)
Number of subjects: 14
Study 7362696 — intervention group
Group type: COMPARATOR
Intervention: Colestipol (20 g/day)
Number of subjects: 14
Study 30407039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 85
Study 30407039 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing integrated with Cognitive-Behavioral Therapy (MI-CBT)
Number of subjects: 85
Study 27807605 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 39
Study 27807605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 27807605 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (during conditioning)
Number of subjects: 39
Study 27807605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after evocation)
Number of subjects: 39
Study 26923487 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal speech
Number of subjects: 96
Study 26923487 — intervention group
Group type: COMPARATOR
Intervention: Tracheoesophageal fistula and Provox 2 voice prosthesis
Number of subjects: 96
Study 26923487 — intervention group
Group type: COMPARATOR
Intervention: Electrolarynx
Number of subjects: 96
Study 25067799 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT) for 6 months
Number of subjects: 11
Study 23069315 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine and adefovir diprivoxil combination therapy (LA)
Number of subjects: 150
Study 23069315 — intervention group
Group type: COMPARATOR
Intervention: lamivudine alone (L)
Number of subjects: 150
Study 23069315 — intervention group
Group type: COMPARATOR
Intervention: adefovir dipivoxil alone (A)
Number of subjects: 150
Study 23069315 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine and adefovir diprivoxil combination therapy (LA) followed by adefovir monotherapy
Number of subjects: 150
Study 19545976 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5 mg)
Number of subjects: 1460
Study 19545976 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (1.5 mg), Perphenazine (8 mg), Ziprasidone (40 mg), Quetiapine (200 mg)
Number of subjects: 1460
Study 17898183 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPH-MeNZB
Number of subjects: 615
Study 17898183 — intervention group
Group type: COMPARATOR
Intervention: MenBvac (control)
Number of subjects: 615
Study 17898183 — intervention group
Group type: EXPERIMENTAL
Intervention: CV-MeNZB
Number of subjects: 615
Study 17898183 — intervention group
Group type: COMPARATOR
Intervention: NIPH-MeNZB (control)
Number of subjects: 615
Study 15138710 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg alone
Number of subjects: 14
Study 15138710 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 200 mg with ketoconazole 400 mg
Number of subjects: 14
Study 12490790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 63
Study 12490790 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 63
Study 9698972 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo drug (sham second drug)
Number of subjects: 42
Study 9698972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no misattribution)
Number of subjects: 42
Study 9698972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachistoscopic display (placebo)
Number of subjects: 42
Study 7696728 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 7696728 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0
Study 2547464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate given together and 30 min after diflunisal tablets
Number of subjects: 0
Study 2547464 — intervention group
Group type: COMPARATOR
Intervention: Diflunisal (oral administration)
Number of subjects: 0
Study 2547464 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of diflunisal
Number of subjects: 0
Study 1103896 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 240 mg orally
Number of subjects: 7
Study 1103896 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil retard, orally
Number of subjects: 7
Study 1103896 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 7
Study 31339232 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy added to guideline-directed medical therapy (GDMT)
Number of subjects: 0
Study 31339232 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 0
Study 31339232 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker doses in ANTHEM-HF
Number of subjects: 0
Study 31339232 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker doses in ANTHEM-HF vs. PARADIGM-HF
Number of subjects: 0
Study 31339232 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
Number of subjects: 0